Pharmacology

Tectonic Therapeutic Appoints Daniel Lochner as Chief Financial Officer

Retrieved on: 
понедельник, июня 3, 2024
Biotechnology, Pharmaceutical, Health, Knowledge, MD, Pharmacology, Oyster Point Pharma, Columbia University, MBA, CFO, Goldman Sachs, GPCR, Acquisition, University, G protein-coupled receptor

Tectonic Therapeutic, Inc. (“Tectonic”), a privately-held biotechnology company developing GPCR (G-protein coupled receptor)-targeted therapeutic proteins, today announced the appointment of Daniel Lochner as Chief Financial Officer of Tectonic.

Key Points: 
  • Tectonic Therapeutic, Inc. (“Tectonic”), a privately-held biotechnology company developing GPCR (G-protein coupled receptor)-targeted therapeutic proteins, today announced the appointment of Daniel Lochner as Chief Financial Officer of Tectonic.
  • “Dan is an experienced public-company CFO who will add significant financial expertise to our team,” said Alise Reicin, MD, President and Chief Executive Officer of Tectonic.
  • Prior to joining Tectonic, he served as Chief Business Officer and Chief Financial Officer of Viatris' Eye Care Division following Viatris’ acquisition of Oyster Point Pharma, where he had previously served as Chief Financial Officer and Chief Business Officer.
  • “I’m honored to be joining the Tectonic team as it advances a pipeline of novel GPCR targeted biologic therapies.”
    Christian Cortis, Ph.D., the current Chief Operating Officer and Chief Financial Officer will be leaving the company to pursue external opportunities.

23andMe Therapeutics Announces Positive Preliminary Phase 2 Safety and Efficacy Results for 23ME-00610, targeting CD200R1, at the 2024 ASCO Annual Meeting

Retrieved on: 
понедельник, июня 3, 2024
Nature, IHC, Aes, Asthma, Histology, ASCO, RECIST, Pharmacology, IO, Ovarian cancer, Fatigue, Patient, Dermatitis, AACR, Annual general meeting, Cancer, Genetics, Safety, Society, Ascites, Psoriasis, Therapy, PR, Genome, Risk, CD200, Death, Neoplasm, Itch, Signature, Nausea, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading human genetics and biopharmaceutical company, announced positive preliminary Phase 2 safety and efficacy data from 23ME-00610, a first-in-class anti-CD200R1 antibody, presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, May 31-June 4.

Key Points: 
  • 23andMe presented two posters on 23ME-00610, one each from neuroendocrine and ovarian cancer patient cohorts in its ongoing Phase 1/2a clinical trial.
  • 23ME-00610 monotherapy demonstrates acceptable safety and tolerability, and achieves the prespecified targets for maximal pharmacology at 1400 mg dosed every three weeks.
  • In addition to CD200, histology data suggest that immunosuppressed (“cold”) tumors may be more likely to exhibit disease control with 23ME-00610.
  • Patients received 1400 mg given IV every 3 weeks until disease progression, and CT/MRI scans were conducted every ~ 8 weeks.

LIXTE Biotechnology Holdings Names Distinguished Oncologist Jan Schellens as Chief Medical Officer

Retrieved on: 
понедельник, июня 3, 2024
Pharmacology, Patient, EMA, Cancer, Utrecht University, Immunotherapy, Docetaxel, Publication, Pharmacy, Leiden University, Prostate cancer, CMO, Growth, Netherlands Cancer Institute, Pharmaceutical industry

(“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical-stage pharmaceutical company developing a new class of cancer therapy to enhance chemotherapy and immunotherapy, today announced the appointment of Jan Schellens, M.D., Ph.D., as Chief Medical Officer (CMO).

Key Points: 
  • (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical-stage pharmaceutical company developing a new class of cancer therapy to enhance chemotherapy and immunotherapy, today announced the appointment of Jan Schellens, M.D., Ph.D., as Chief Medical Officer (CMO).
  • Dr. Schellens brings to LIXTE more than 25 years of clinical experience as a medical oncologist, pharmacologist and clinical pharmacologist, including more than two decades developing and bringing new drugs to market.
  • Schellens is a widely respected medical professional who has been at the forefront of oncology throughout his career,” said Bas van der Baan, LIXTE’s Chief Executive Officer.
  • degree, and he served as a board member and Chief Medical Officer of Byondis B.V. in Nijmegen, Netherlands through September 2023.

Coya Therapeutics Announces Acceptance of Peer-Reviewed Manuscript in the Medical Journal: Frontiers in Neurology

Retrieved on: 
понедельник, июня 3, 2024
Research, Neurology, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Safety, Interleukin 2, MDA, Episcopal conference, Manuscript, Frontiers, Therapy, Biomarker, ALS, Muscular Dystrophy Association, COYA, Combination, Pharmacology, Conference

Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologic intended to enhance regulatory T cell (Treg) function, announces the acceptance of a peer-reviewed manuscript titled, “A Phase 1 Proof-of-Concept Study Evaluating Safety, Tolerability, and Biological Marker Responses with Combination Therapy of CTLA4-Ig and Interleukin-2 in Amyotrophic Lateral Sclerosis,” in the medical journal Frontiers in Neurology.

Key Points: 
  • Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologic intended to enhance regulatory T cell (Treg) function, announces the acceptance of a peer-reviewed manuscript titled, “A Phase 1 Proof-of-Concept Study Evaluating Safety, Tolerability, and Biological Marker Responses with Combination Therapy of CTLA4-Ig and Interleukin-2 in Amyotrophic Lateral Sclerosis,” in the medical journal Frontiers in Neurology.
  • A portion of the data from the manuscript was previously presented at the 2023 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference and the 2024 Society of Neuroimmune Pharmacology Conference.
  • “The publication in a peer-reviewed medical journal of these promising proof of concept clinical data of the combination of Low Dose IL-2 and CTLA4-Ig in people with ALS is continued important validation for our approach to addressing this devastating condition,” said Dr. Fred Grossman, Coya’s Chief Medical Officer.

Kynexis Appoints Esteemed Scientific Advisory Board Members to Advance Precision Therapeutics for Brain Diseases

Retrieved on: 
среда, мая 29, 2024
Neuroscience, FDA, Drug development, Pediatrics, Drug discovery, Distinguishing, Mental health, Research, Therapy, ALS, Pharmacology, Human, Translational research, Ageing, Multiple sclerosis, Myenteric plexus, CNS, Division, Cognition, University, Clinical trial, DSM-IV codes, Regulatory affairs, Genetics, Associate, SAB, Schizophrenia, CIAS, Patient, Organization, NIMH, Duke University Hospital, Biomarker, Abstract, Brain, Deficit spending, Pharmaceutical industry

NAARDEN, The Netherlands, May 29, 2024 (GLOBE NEWSWIRE) -- Kynexis, a clinical-stage biotechnology company focused on precision therapeutics by leveraging biomarkers and human genetics for brain diseases, announced today the formation of its distinguished Scientific Advisory Board (SAB).

Key Points: 
  • NAARDEN, The Netherlands, May 29, 2024 (GLOBE NEWSWIRE) -- Kynexis, a clinical-stage biotechnology company focused on precision therapeutics by leveraging biomarkers and human genetics for brain diseases, announced today the formation of its distinguished Scientific Advisory Board (SAB).
  • "At Kynexis, we are committed to restoring brain function to enable a better life for people with schizophrenia,” said Kees Been, Chief Executive Officer at Kynexis.
  • Robert Schwarcz, Ph.D., is a Scientific Co-founder of Kynexis and Professor of Psychiatry, Pharmacology and Pediatrics at the University of Maryland Baltimore.
  • Based on these insights, he co-founded Kynexis to develop fundamentally new interventions for the prevention and treatment of brain dysfunctions in humans.

Vir Biotechnology Appoints Mark Eisner, M.D., M.P.H. as Chief Medical Officer

Retrieved on: 
среда, мая 29, 2024
AIDS, Health, Infectious Diseases, Health Technology, Clinical Trials, Pharmaceutical, Biotechnology, Pharmacology, Patient, School of Public Health, Biology, Genentech, Stanford University, University, Epidemiology, Publication, MBA, CMO, Medicine, School, Infection, Public health, Ophthalmology

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Mark D. Eisner, M.D., M.P.H.

Key Points: 
  • Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Mark D. Eisner, M.D., M.P.H.
  • will join the company as Executive Vice President and Chief Medical Officer (CMO), effective June 03, 2024.
  • Dr. Eisner will be a part of the company’s Executive Management Team and will report directly to Marianne De Backer, M.Sc., Ph.D., MBA, Vir’s Chief Executive Officer.
  • In this role, he led all development functions which included biometrics, regulatory, clinical science, clinical operations, drug safety, and pharmacology.

Cytokinetics and Royalty Pharma Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline

Retrieved on: 
среда, мая 22, 2024
Pharmacology, Patient, Risk, Research and development, Heart failure, FDA, Commercial, SAN, HCM, EMA, Morrison & Foerster, P.C, Cooley LLP, Pharmaceutical industry

“This is our third transaction with Cytokinetics and highlights our ability to structure creative, win-win funding solutions and underscores the breadth of our funding capabilities.

Key Points: 
  • “This is our third transaction with Cytokinetics and highlights our ability to structure creative, win-win funding solutions and underscores the breadth of our funding capabilities.
  • If Royalty Pharma does not opt-in to fund Phase 3 development, Royalty Pharma will receive a 1.0% royalty on annual net sales of CK-586.
  • Equity Purchase: Royalty Pharma will purchase $50 million of Cytokinetics’ common stock in a private placement that will be concurrent with the underwritten public offering that Cytokinetics plans to launch today.
  • Goodwin Procter LLP, Fenwick & West LLP, Maiwald GmbH, and Wolf, Greenfield & Sacks, P.C., acted as legal advisors to Royalty Pharma.

Royalty Pharma and Cytokinetics Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline

Retrieved on: 
среда, мая 22, 2024
Pharmacology, Patient, Risk, Research and development, Heart failure, FDA, HCM, EMA, LLP, Morrison & Foerster, P.C, Cooley LLP, Pharmaceutical industry

“We are excited to support Cytokinetics as the company advances towards commercialization of aficamten,” said Pablo Legorreta, Royalty Pharma’s founder and Chief Executive Officer.

Key Points: 
  • “We are excited to support Cytokinetics as the company advances towards commercialization of aficamten,” said Pablo Legorreta, Royalty Pharma’s founder and Chief Executive Officer.
  • “This is our third transaction with Cytokinetics and highlights our ability to structure creative, win-win funding solutions and underscores the breadth of our funding capabilities.
  • If Royalty Pharma does not opt-in to fund Phase 3 development, Royalty Pharma will receive a 1.0% royalty on annual net sales of CK-586.
  • Goodwin Procter LLP, Fenwick & West LLP, Maiwald GmbH, and Wolf, Greenfield & Sacks, P.C., acted as legal advisors to Royalty Pharma.

Anavex Life Sciences Announces Expansion of Leadership Team

Retrieved on: 
среда, мая 22, 2024
Marketing, Drug, Gen-Probe, European Medicines Agency, FDA, Drug development, North Carolina State University, Senior, Rett syndrome, HCV, Therapy, Pharmacology, Clinical research, Ritonavir, MD, James Madison University, Ipilimumab, AbbVie, CNS, Clinical pharmacology, Bristol Myers Squibb, New Drug Application, Arena Pharmaceuticals, Nobel Prize, Schizophrenia, Nivolumab, Amylin Pharmaceuticals, Yale University, Molecular biology, Pharmacokinetics, Doctor of Philosophy, Acer, Rochester Institute of Technology, Research and development, University, Overalls, Pramlintide, Intercept Pharmaceuticals, DSM-IV codes, Assistant, EMA, DMPK, Roche, Development, Central nervous system, Pharmaceutical industry

“The most important part of building a long-term, commercially sustainable, growing business is putting the right players on the field,” said Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex.

Key Points: 
  • “The most important part of building a long-term, commercially sustainable, growing business is putting the right players on the field,” said Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex.
  • Prior to Anavex Dr. Lopez-Talavera held key leadership positions at Fractyl Health, Intercept Pharmaceuticals, AbbVie, Bristol Myers Squibb and Roche.
  • Dr. Edwards brings to Anavex 18 years of experience in various aspects of drug development including DMPK (drug metabolism and pharmacokinetics), Clinical Pharmacology, and Clinical Science.
  • Before joining Anavex, Dr. Edwards served as Vice President of Clinical Science at Acer Therapeutics, and positions of increasing responsibility at Madrigal Pharmaceuticals, Intercept Pharmaceuticals, Amylin Pharmaceuticals, and Arena Pharmaceuticals.

South Rampart Pharma Publishes SRP-001's Unique Pain Relief Mechanism and Phase 1 Trial Results in Scientific Reports

Retrieved on: 
четверг, мая 16, 2024
RCT, Pharmacology, Half-life, Nonsteroidal anti-inflammatory drug, Patient, Pharmacokinetics, TRPV4, Ochsner Health System, Toxicity, Randomized controlled trial, Abuse, Liver, Prevalence, Scientific Reports, PAG, Safety, CNR1, PKS, AM404, Neuropathic pain, FAAH, Kidney, Gene, GLP, Brain, Mortality, Paracetamol, NAPQI, TRPV1, Pain, Hepatotoxicity, Science, CNR2, Pharmaceutical industry

NEW ORLEANS, May 16, 2024 (GLOBE NEWSWIRE) -- South Rampart Pharma, Inc., today announced the publication of a paper in Scientific Reports describing the manner in which SRP-001 works in the brain to alleviate pain and the results of a Phase 1 randomized controlled trial (RCT)1.

Key Points: 
  • NEW ORLEANS, May 16, 2024 (GLOBE NEWSWIRE) -- South Rampart Pharma, Inc., today announced the publication of a paper in Scientific Reports describing the manner in which SRP-001 works in the brain to alleviate pain and the results of a Phase 1 randomized controlled trial (RCT)1.
  • The study, by Bazan et al., is titled, " Transcriptomic signature, bioactivity and safety of a non-hepatotoxic analgesic generating AM404 in the midbrain PAG region ."
  • The publication reveals SRP-001's unique mechanism of action, producing higher amounts of N-arachidonoylphenolamine (AM404) than acetaminophen, a metabolite crucial for inducing pain relief in the midbrain’s periaqueductal grey (PAG) region.
  • Armed with known mechanisms for pain relief in the brain and compelling Phase 1 randomized trial data, we look forward to advancing SRP-001 into Phase 2 randomized and controlled studies for acute and neuropathic pain in the second half of 2024.”